



File 16051-9US CC/DBB/jrl

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew VAILLANT et al.
Serial number: 10/661,088
Filing date: September 12, 2003
For: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV
Art Unit: 1648
Examiner: Bo, PENG
Agent: Christian CAWTHORN

TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321(c)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A.

Sir:

Petitioner, REPLICOR INC., the Assignee and the 100% owner of the invention disclosed in the above-captioned application and of co-pending U.S. Application Nos. 10/661,403, 10/661,402, 10/661,415 and 10/969,812, hereby disclaim, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§154 to 156 and 173, of U.S. copending application Nos. 10/661,403, 10/661,402, 10/661,415 and 10/969,812, and agree that any patent granted on the above-captioned patent application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to said U.S. copending application Nos. 10/661,403, 10/661,402, 10/661,415 and 10/969,812, this agreement to run with said U.S. Patent application No. 10/661,088 which are commonly owned applications, and any patent granted on the above-captioned patent application and to be binding upon the grantee, its successors or assigns.

07/25/2007 SZEWDIE1 08000098 195113 10661088

02 FC:2814 65.00 DA

Assistant Commissioner for Patents

In making the above disclaimer, REPLICOR INC. does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of any patent granted on said U.S. Patent copending application Nos. 10/661,403, 10/661,402, 10/661,415 and 10/969,812 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a Court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims cancelled by reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term. In addition, any patent granted on that application or any patent subject to the reexamination proceeding shall be enforceable only for and during such period that said patent is commonly owned with the application or patent which formed the basis for the judicially created double patenting.

The Commissioner is hereby authorized to charge fees of \$65.00, or any appropriate fees that may be required by this paper, since the Applicants requested the status of small entity, under 37 C.F.R. § 1.20(d). The Commissioner is hereby authorized to charge and to credit any overpayment to Deposit Account No. 19-5113.

Respectfully,



Christian Cawthorn, Reg. No. 47,352
Agent for Applicants
Tel: (514) 847-4256
Fax: (514) 288-8389

July 23, 2007

Date

OGILVY RENAULT LLP
1981 McGill College, Suite 1600
Montreal, Quebec H3A 2Y3
CANADA